<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02607410</url>
  </required_header>
  <id_info>
    <org_study_id>MERS2015</org_study_id>
    <nct_id>NCT02607410</nct_id>
  </id_info>
  <brief_title>Sitagliptin (DPP-4 Inhibitor) and NPH Insulin in Patients With T2D</brief_title>
  <official_title>Short and Long Term Effects of a Dypeptidil-peptidase-4 Versus Bedtime NPH Insulin as add-on Therapy in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the short and long term effects of inhibitor of the DPP-IV enzyme, sitagliptin ,
      with bedtime NPH insulin in patients with T2D inadequately controlled with sulphonylurea plus
      biguanide: effects on beta cell function and on metabolic profile.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glucose control is fundamental in the treatment of type 2 diabetes (DM2). Studies suggest
      that drugs that boost levels of glucagon-like peptide (GLP-1) improve glycemic control and
      have long-term beneficial effect on the function of pancreatic beta cells. Objective: To
      compare the short and long term effects of sitagliptin (which inhibits the DPP-IV enzyme,
      increasing the levels of GLP-1) with bedtime NPH insulin in patients with T2D inadequately
      controlled with sulphonylurea plus biguanide. Effects on beta cell function and on metabolic
      profile were analyzed. Methods: 40 patients with DM2, HbA1c between 6.6 to 10%, in use of
      metformin and glibenclamide will be randomized to the addition of sitagliptin (Sitagliptin
      Group) or of bedtime NPH insulin (NPH Group). Measurements of HbA1c, metabolic and hormonal
      profile at fasting and post-meal (every 30 minutes for 4 hours) will be evaluated before and
      after 6 months (short term) and 12 months (long term) of adding sitagliptin or NPH insulin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement in HbA1c levels</measure>
    <time_frame>six and twelve months</time_frame>
    <description>Changes in fasting blood levels of HBA1c (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>improvement of beta cell function with a meal test</measure>
    <time_frame>six and twelve months after each therapy at times zero, 30, 60, 120 and 180 minutes after meal test</time_frame>
    <description>Changes in serum C-peptide levels (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement on alpha cell function with a meal test</measure>
    <time_frame>six and twelve months after each therapy at times zero, 30, 60, 120 and 180 minutes after meal test</time_frame>
    <description>Changes in plasma glucagon levels (pg/mL)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100mg every day of sitagliptin in patients that were previosly using metformin and glyburide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPH insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NPH insulin will be applied bedtime every night in patients that awere previously using metformin and glyburide,The insulin dosage will be adjusted to fasting glycemia between 90 and 100 mg / dL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin</intervention_name>
    <description>patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year</description>
    <arm_group_label>sitagliptin</arm_group_label>
    <other_name>DPP-4 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPH insulin</intervention_name>
    <description>patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year</description>
    <arm_group_label>NPH insulin</arm_group_label>
    <other_name>long-acting insulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  outpatients with T2D inadequately controlled with metformin plus glyburide

          -  HbA1c levels between 6.6 and 10%

          -  body mass index &lt; 35 kg/m2

        Exclusion Criteria

          -  heart failure

          -  respiratory failure

          -  uncontrolled hypertension

          -  impaired hepatic function

          -  impaired reanl function

          -  endocrine disorder

          -  gastrointestinal disorder

          -  malignancy

          -  alcohol abuse

          -  previous use of insulin

          -  previou use of based incretin therapy

          -  type 1 diabetes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria ER Siva, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Sao Paulo General Hospital</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Muscelli E, Casolaro A, Gastaldelli A, Mari A, Seghieri G, Astiarraga B, Chen Y, Alba M, Holst J, Ferrannini E. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab. 2012 Aug;97(8):2818-26. doi: 10.1210/jc.2012-1205. Epub 2012 Jun 8.</citation>
    <PMID>22685234</PMID>
  </reference>
  <reference>
    <citation>Aulinger BA, Bedorf A, Kutscherauer G, de Heer J, Holst JJ, Göke B, Schirra J. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade. Diabetes. 2014 Mar;63(3):1079-92. doi: 10.2337/db13-1455. Epub 2013 Dec 2.</citation>
    <PMID>24296715</PMID>
  </reference>
  <reference>
    <citation>Retnakaran R, Qi Y, Opsteen C, Vivero E, Zinman B. Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin. Diabetes Obes Metab. 2010 Oct;12(10):909-15. doi: 10.1111/j.1463-1326.2010.01254.x.</citation>
    <PMID>20920044</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2015</study_first_submitted>
  <study_first_submitted_qc>November 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2015</study_first_posted>
  <last_update_submitted>November 17, 2015</last_update_submitted>
  <last_update_submitted_qc>November 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo General Hospital</investigator_affiliation>
    <investigator_full_name>Maria Elizabeth Rossi da Silva</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>sitagliptin</keyword>
  <keyword>NPH insulin</keyword>
  <keyword>GLP-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Isophane insulin, beef</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Glyburide</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
    <mesh_term>Isophane Insulin, Human</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

